Home › Dyslipidemias › NCT06496243

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria:

* Lp(a): \>=50 mg/dL (\>=125 nmol/L) for cohort 1 (FILLED) and Lp(a) \>= 20 mg/dL (\>= 50 nmol/L) to \<50 mg/dL (\< 125 nmol/L) for cohort 2
* LDL-C \>70 mg/dL
* TG \< 400mg/dL (\<4.52 mmol/L)

Exclusion Criteria:

* HbA1c\>=10 or FPG \>=270 mg/dL
* CV events within 3 months of screen

About the study

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab

Patients will:

Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

What is being tested

• obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks (drug)

Sponsor: NewAmsterdam Pharma · Participants: 69 · Started: Dec 2, 2024

Contact the study team

• Ashley Walker · Phone: 919 641 5724

Official record on ClinicalTrials.gov — NCT06496243

Locations in the U.S.

Conditions

• Dyslipidemias

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.